Trelegy (fluticasone, umeclindinum and vilanterol)
CareOregon recently added a new triple ingredient inhaler (ICS/LAMA/LABA) called Trelegy Ellipta to the formulary. Trelegy is a cost-effective product that could be used for:
- Patients with persistent COPD symptoms, while on a two-ingredient inhaler (Advair, Symbicort, AirDuo, Stiolto, Anoro, Dulera etc.).
- Patients currently using two inhalers, such as Advair + Spiriva. Using Trelegy saves about $290 per month over using two separate inhalers.
Patients who fall into either of the above categories do NOT require a prior authorization to use Trelegy. It does require a prior authorization if the patient does not fit one of the above scenarios.
Please consider transitioning patients currently on two separate inhalers to Trelegy. This one-puff, once-a-day inhaler may improve patient adherence and reduce the cost of multiple inhalers.